Takeda's gout drug febuxostat headed for US FDA panel
This article was originally published in Scrip
Executive Summary
Takeda's NDA for the gout treatment Uloric (febuxostat) will be the focus of a November 24th review by the US FDA's arthritis advisory panel. The proposed indication is treatment of hyperuricaemia in patients with gout. This will be the third go-around in the US for the oral selective xanthine oxidase inhibitor, which has been the subject of two previous approvable letters from the FDA. The compound is licensed from Japan's Teijin Pharma, and Takeda gained the US rights through the unwinding of its TAP Pharmaceuticals joint venture with Abbott.
You may also be interested in...
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.
Preterm Birth Prevention Studies Need To Look Beyond Makena Endpoints, Experts Say
Gestational age and a binary, neonatal composite endpoint are insufficient to assess outcomes that are important to babies and families, clinicians and researchers say, suggesting development of continuous variables or scales with weighted components and a comparison of outcomes among newborns in gestational age ‘buckets.’